Page 760 - Basic _ Clinical Pharmacology ( PDFDrive )

746 SECTION VII Endocrine Drugs

REFERENCES Imai Y et al: Nuclear receptors in bone physiology and diseases. Physiol Rev
2013;93:481.
Acconcia F et al: Palmitoylation-dependent estrogen receptor alpha membrane
localization: Regulation by 17beta-estradiol. Mol Biol Cell 2005;16:231. Kalantaridou S, Chrousos GP: Monogenic disorders of puberty. J Clin Endocrinol
Metab 2002;87:2481.
Anderson GL et al for the Women’s Health Initiative Steering Committee: Effects
of conjugated equine estrogen in postmenopausal women with hysterectomy. Kalantaridou S et al: Premature ovarian failure, endothelial dysfunction, and
JAMA 2004;291:1701. estrogen-progesterone replacement. Trends Endocrinol Metab 2006;17:101.
Bacopoulou F, Greydanus DE, Chrousos GP: Reproductive and contraceptive Kalantaridou SN et al: Impaired endothelial function in young women with
issues in chronically ill adolescents. Eur J Contracept Reprod Health Carez premature ovarian failure: Normalization with hormone therapy. J Clin
2010;15:389. Endocrinol Metab 2004;89:3907.
Basaria S et al: Adverse events associated with testosterone administration. N Engl Kanaka-Gantenbein C et al: Assisted reproduction and its neuroendocrine impact
J Med 2010;363:109. on the offspring. Prog Brain Res 2010;182C:161.
Baulieu E-E: Contragestion and other clinical applications of RU 486, an antipro- Lidegaard Ø et al: Thrombotic stroke and myocardial infarction with hormonal
gesterone at the receptor. Science 1989;245:1351. contraception. N Engl J Med 2012;366:2257.
Bechlioulis A et al: Endothelial function, but not carotid intima-media thickness, Livadas S, Chrousos GP: Control of the onset of puberty. Curr Opin Pediatr
is affected early in menopause and is associated with severity of hot flushes. 2016;28:551.
J Clin Endocrinol Metab 2010;95:1199. Manson JE et al: Estrogen plus progestin and the risk of coronary heart disease.
Bhupathiraju SN et al: Exogenous hormone use: oral contraceptives, postmeno- N Engl J Med 2003;349:523.
pausal hormone therapy, and health outcomes in the Nurses’ Health Study. Martin KA, Barbieri RL: Menopausal hormone therapy: Benefits and risks.
Am J Pub Health 2016;106:1631. UpToDate 2016.
Binkhorst L, et al: Augmentation of endoxifen exposure in tamoxifen-treated McDonnell DP, Wardell SE: The molecular mechanisms underlying the pharma-
women following SSRI switch. Clin Pharmacokin 2016;55:259. cological actions of ER modulators: Implications for new drug discovery in
Böttner M, Thelen P, Jarry H: Estrogen receptor beta: Tissue distribution and the breast cancer. Curr Opin Pharmacol 2010;10:620.
still largely enigmatic physiological function. J Steroid Biochem Mol Biol Merke DP et al: Future directions in the study and management of congenital
2014;139:245. adrenal hyperplasia due to 21-hydroxylase deficiency. Ann Intern Med
Burkman R, Schlesselman JJ, Zieman M: Safety concerns and health benefits asso- 2002;136:320.
ciated with oral contraception. Am J Obstet Gynecol 2004;190(Suppl 4):S5. Naka KK et al: Effect of the insulin sensitizers metformin and pioglitazone on
Chlebowski RT et al: Estrogen plus progestin and breast cancer incidence and endothelial function in young women with polycystic ovary syndrome: A
mortality in postmenopausal women. JAMA 2010;304:1684. prospective randomized study. Fertil Steril 2011;95:203.
Chrousos GP: Perspective: Stress and sex versus immunity and inflammation. Nelson HD et al: Use of medication to reduce risk for primary breast cancer: A
Sci Signal 2010;3:pe36. systematic review for the U.S. Preventive Services Task Force. Ann Intern
Med 2013;158:604.
Chrousos GP, Torpy DJ, Gold PW: Interactions between the hypothalamic-
pituitary-adrenal axis and the female reproductive system: Clinical implica- Paulmurugan R et al: In vitro and in vivo molecular imaging of estrogen receptor
tions. Ann Intern Med 1998;129:229. α and β homo- and heterodimerization: exploration of new modes of recep-
tor regulation. Mol Endocrinol 2011;25:2029.
Coomarasamy A et al: A randomized trial of progesterone in women with recurrent
miscarriages. N Engl J Med 2015;373:2141. Price VH: Treatment of hair loss. N Engl J Med 1999;341:964.
Cui J, Shen Y, Li R: Estrogen synthesis and signaling pathways during aging: From Rossouw JE et al: Risks and benefits of estrogen plus progestin in healthy post-
periphery to brain. Trends Mol Med 2013;19:197. menopausal women: Principal results from the Women’s Health Initiative
randomized controlled trial. JAMA 2002;288:321.
Cuzick J et al: SERM Chemoprevention of Breast Cancer Overview Group:
Selective oestrogen receptor modulators in prevention of breast cancer: An Scher HI et al: Increased survival with enzalutamide in prostate cancer after
updated meta-analysis of individual participant data. Lancet 2013;381:1827. chemotherapy. N Engl J Med 2012;367:1187.
Diamanti-Kandarakis E et al: Pathophysiology and types of dyslipidemia in PCOS. Smith RE: A review of selective estrogen receptor modulators in national
Trends Endocrinol Metab 2007;18:280. surgical adjuvant breast and bowel project clinical trials. Semin Oncol
2003;30(Suppl 16):4.
Finkelstein JS et al: Gonadal steroids and body composition, strength, and sexual
function in men. N Engl J Med 2013;369:1011. Snyder PJ et al: Effect of testosterone replacement in hypogonadal men. J Clin
Endocrinol Metab 2000;85:2670.
Fuqua SAW, Schiff R: Mechanisms of action of selective estrogen receptor modula-
tors and down regulators. UpToDate 2016; topic 762. Stegeman BH et al: Different combined oral contraceptives and the risk of venous
thrombosis: Systematic review and network meta-analysis. Brit Med J
Gomes MPV, Deitcher SR: Risk of venous thromboembolic disease associated 2013;347:f5298.
with hormonal contraceptives and hormone replacement therapy: A clinical
review. Arch Intern Med 2004;164:1965. U.S. Preventive Services Task Force: Hormone therapy for the prevention of chronic
conditions in postmenopausal women. Ann Intern Med 2005;142:855.
Hall JM, McDonnell DP, Korach KS: Allosteric regulation of estrogen recep-
tor structure, function, and co-activator recruitment by different estrogen Wehrmacher WH, Messmore H: Women’s Health Initiative is fundamentally
response elements. Mol Endocrinol 2002;16:469. flawed. Gend Med 2005;2:4.
Harman SM et al: Longitudinal effects of aging on serum total and free testoster- Zandi PP et al: Hormone replacement therapy and incidence of Alzheimer’s disease
one levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin in older women. JAMA 2002;288:2123.
Endocrinol Metab 2001;86:724.
C ASE STUD Y ANSWER

The patient should be advised to start daily transdermal and normal monthly uterine bleeding resume. She should
estradiol therapy (100 mcg/d) along with oral natural pro- also be advised to get adequate exercise and increase
gesterone (200 mg/d) for the last 12 days of each 28-day her calcium and vitamin D intake as treatment for her
cycle. On this regimen, her symptoms should disappear osteoporosis.